Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cleveland Clinic

www.clevelandclinic.org

Latest From Cleveland Clinic

Tech Transfer Roundup: How To Protect Downstream Rights

A review of tech transfer deals over 10 years shows that licensees often protect their value positions to limit royalties paid out to licensors. Meanwhile, licensors often protect their future rights with language recognizing that additional parties may be involved in producing a final product.

Deals Intellectual Property

Medtech 2018: The Place For Innovation As Value-based Health Care Gains Momentum

2017 was a watershed year in many respects, politically, economically and commercially for many players in the medtech field. Where will the opportunities lie in 2018, will breakthrough medtech innovation still have a place among providers often riding on fumes when it comes to budgets, and is it all as bad as some would make out?

International Medical Device

Medtechs At The Wheel In New Health Care Landscape

2016 was a year of surprise and change in political circles, but that's nothing new for the medtech industry, which over a number of years has become accustomed to health care systems demanding different and ever-higher levels of service. Smart medtechs have been ahead of the curve, but the whole industry now factors in clients' wider needs in a holistic approach to patient care. Many companies' current M&A policies are already reflecting the changes to come.

M & A Deals

Cancer Moonshot To Tackle Hereditary Colon Cancer Screening

One of the recent recommendations for a Cancer Moonshot demonstration program is to implement genetic testing on a wider scale in family members of people with colon cancer-associated genetic mutations. But with greater visibility, how should the testing paradigm change?

Innovation Diagnostics
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register